Jazz Pharmaceuticals (JAZZ) Equity Ratio (2010 - 2026)

Jazz Pharmaceuticals' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.38 for Q1 2026.

• In Q1 2026, Equity Ratio rose 5.59% year-over-year to 0.38; the TTM figure through Mar 2026 stood at 0.38 (up 5.59% YoY), while the FY2025 annual figure was 0.37, up 8.69% from the prior year.
• Equity Ratio was 0.38 for Q1 2026 at Jazz Pharmaceuticals, up from 0.37 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.38 in Q1 2026 to a low of 0.26 in Q3 2022.
• Historically, Equity Ratio has averaged 0.33 across 5 years, with a median of 0.33 in 2023.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio tumbled 45.45% in 2022, then rose 17.81% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.28 in 2022, then advanced by 15.17% to 0.33 in 2023, then climbed by 3.9% to 0.34 in 2024, then rose by 8.69% to 0.37 in 2025, then increased by 3.18% to 0.38 in 2026.
• The last three Equity Ratio figures came in at 0.38 (Q1 2026), 0.37 (Q4 2025), and 0.35 (Q3 2025), per Business Quant data.